# Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia

> **NCT02827617** · — · COMPLETED · sponsor: **Oncology Institute of Southern Switzerland** · enrollment: 56 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02827617
- **Lead sponsor:** Oncology Institute of Southern Switzerland
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2024-05-16
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02827617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02827617, "Identification of Biomarkers That Are Predictive of Early Ibrutinib Treatment Failure in High Risk TP53 Mutated Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02827617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*